Biological Active Reagents

Inhibitor of the Cell_cycle>cell cycle from G0/G1 to S phase with powerful antiparasite activity

Novel TLR2 agonist as potential adjuvant for cancer vaccines

Potent serotonin-3 (5-HT3) receptor antagonist

Novel Ras-Signaling Modulator, targeting acyl protein thioesterase 1 (APT1) and 2 (APT2) in cells

Potent dual dopamine-serotonin (DA/5-HT) releaser

Full DAT/5-HT transporter substrate; Non-neurotoxic releasing agent of serotonin, norepinephrine, and dopamine; Full agonist at 5-HT2B and partial agonist at 5-HT2C

Novel selective LYPLAL1 activator, increasing LYPLAL1’s catalytic activity likely by enhancing the efficiency of the catalytic triad charge-relay system, confering beneficial effects in a mouse model of diet-induced obesity

Full DAT/5-HT transporter substrate

Partial DAT/5-HT transporter substrate

Novel potent and selective inhibitor of protein arginine deiminase 3 (PAD3), having 15600 kinact/KI values and ≥10-fold selectivity for PAD3 over PADs 1, 2, and 4.

Novel glutathione-S-transferase-p-activated nitric oxide donor, inhibiting proliferation and inducing apoptosis by targeting PI3K/AKT/mTOR and MEK/ERK pathways in hepatocellular carcinoma cells

Photoswitchable epithelial sodium channel (ENaC) blocker

Novel partial agonist of peroxisome proliferator-activated receptor-γ (PPARγ), recruiting PPARγ-coactivator-1α, preventing triglyceride accumulation, and potentiating insulin signaling in vitro

Pseudomonas aeruginosa autoinducer

Novel potent inhibitor of the AAA+ ATPase p97

Novel potent inhibitor of the AAA+ ATPase p97

Neuroprotective agent, protecting ventral horn spinal cord motor neurons from cell death

Novel bFGF antagonist peptide, inhibiting breast cancer cell growth

Novel inhibitor of atherogenesis and diabetes, significantly and specifically inhibiting αD-CEP binding

Novel reactivator of mutant p53, fuctioning as a zinc metallochaperone (ZMC) with diminished copper binding that functions as a chemotherapy and radiation sensitizer

Novel modulator of p53 activity, arresting at G2/M phase inducing delay of cell cycle progression

Selective spleen tyrosine kinase (SYK) inhibitor, suppressing leukocyte immune function and inflammation, and leading to a reduction in arthritis score and attenuated histological damage

Novel P2Y1 Antagonist

Second-generation active site-targeted covalent irreversible inhibitor of USP7

Novel INK4C inhibitor, specifically blocking the bioactivity of p18 protein

Novel INK4C inhibitor, specifically blocking the bioactivity of p18 protein

Novel INK4C inhibitor, specifically blocking the bioactivity of p18 protein

Novel p18(INK4C) inhibitor

δ-Opioid receptor agonist